CytomX disclosed clinical data from late‑line metastatic colorectal cancer patients treated with its antibody‑drug conjugate varsetatug masetecan (Varseta‑M), reporting responses across multiple dose levels, the company said in a corporate release summarized in industry coverage. The data arrive amid an active ADC landscape in solid tumors where payload, linker, and target expression shape activity and safety. The same roundup also noted an FDA label expansion for Cosentyx; regulators and investors are parsing how ADCs and established biologics are being repositioned across indications.